IMMP - Immutep granted Australian patent related to lead product candidate

Immutep (NASDAQ:IMMP) announced on Friday that the Australian Patent Office awarded the company a new patent covering the therapeutic combinations of its lead immunotherapy candidate eftilagimod alpha and a PD-1 pathway inhibitor. Also called efti or IMP32, eftilagimod alpha is a LAG-3 fusion protein (LAG-3Ig) currently undergoing studies for cancer and infectious diseases. The new patent (number 2016205983) titled “Combined Preparations for the Treatment of Cancer or Infection” is set to expire in Jan. 2036. “The LAG-3 / MHC class II immune control mechanism has attracted significant interest from the medical and investment communities in recent weeks,” after a peer-reviewed publication of its Phase 3 data, CEO Marc Voigt, noted. The company was granted similar patents in Europe, the U.S., and China, as announced in 2018 – 2021.

For further details see:

Immutep granted Australian patent related to lead product candidate